Agilisium Achieves AWS Life Sciences Competency Status

LOS ANGELES, July 30, 2024 /PRNewswire/ — Agilisium, a pioneering leader in Data Analytics, Cloud, and Life Science solutions, today announced that it has won the coveted AWS Life Sciences Competency status; placing the brand among an exclusive group of 28 Consulting Partners out of 8,300+ AWS Partners globally. This remarkable achievement demonstrates the company’s proven expertise in delivering transformative cloud solutions to pharmaceutical companies, seeking to expedite drug discovery, strengthen clinical trials, and develop novel genetic-based treatments.

Agilisium is an AWS Life Sciences Competency Partner with 20+ GenAI-powered Data Analytics Solutions for Pharma Business

Agilisium has developed over 20 GenAI-powered data analytics solutions exemplifying the company’s innovative approach, enabling pharma organizations to unlock deeper insights, and accelerate research and development cycles; thereby bringing life-saving treatments to patients more efficiently. Furthermore, Agilisium’s solutions and accelerators can be accessed through the AWS marketplace.

Commenting on the achievement, Mr. Raj Babu, Founder and CEO of Agilisium said, “Earning the AWS Life Sciences Competency status is a significant milestone for Agilisium. This achievement reflects our team’s unwavering dedication to understanding the complex challenges in the pharma industry and developing solutions that effectively address them. By harnessing the power of our GenAI solutions, we are confident that we can usher in a new era of data-driven discovery and innovation in life sciences. Additionally, this recognition would enable our clients to transform data into meaningful insights, ultimately delivering life-changing therapies to patients faster, globally.”

As one of the few AWS-certified Data Analytics partners with specialized expertise in the pharmaceutical industry, Agilisium is uniquely positioned to offer a wide range of AWS services tailored for the Life Sciences industry. This includes generative AI solutions, advanced analytics, data lakes, and machine learning, among several others. The company also offers AWS’ MAP (Migration Acceleration Program) funding program and No-Cost Assessment program for its clients which significantly helps clients to accelerate faster Cloud Transformation journeys.

About Agilisium – Agilisium is one of the premier Life Sciences partners for digital innovations. The company delivers cutting-edge solutions that drive impactful change by combining our strong domain expertise with Data, Cloud, GenAI, and Advanced Analytics. Agilisium collaborates with leading pharma and biotech companies to provide data-driven insights and innovative solutions across the value chain, helping accelerate drug discovery, optimize patient care, achieve commercial success, streamline product delivery, and foster collaboration. Learn more at www.Agilisium.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/agilisium-achieves-aws-life-sciences-competency-status-302210118.html

SOURCE Agilisium Consulting

Staff

Recent Posts

Daily Fit Notes Rolls Out Affordable Fitness Solutions for the Modern Lifestyle

Daily Fit Notes, founded by Justin Brey in New York, launches a text-based subscription fitness…

1 day ago

WillowWood Rebrand by DD.NYC Wins Gold Anthem Award for Product and Innovation in 2024 Rebrand

MT. STERLING, Ohio, Dec. 20, 2024 /PRNewswire/ -- WillowWood, a global leader in prosthetic solutions,…

2 days ago

Quantum Biopharma Announces Closing of Second Tranche

TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"…

2 days ago

Glow Lifetech Announces Completion of Final Payment under Swiss Pharma Share Exchange Agreement and Debt Settlement

Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…

2 days ago